Professional Documents
Culture Documents
Name Dosage Form (S) Adult Dose Adverse Events Nucleoside Reverse Transcriptase Inhibitors (Nrtis)
Name Dosage Form (S) Adult Dose Adverse Events Nucleoside Reverse Transcriptase Inhibitors (Nrtis)
Dosage Adult Dose Form(s) Nucleoside reverse transcriptase inhibitors (NRTIs) Abacavir (Ziagen) 300-mg tablet; 600 mg PO q 20-mg/mL oral or solution 300 mg PO bi 'i anosine ((i e)) *2+-mg% 200mg% 2+0-mg% ,00-mg entericcoate ca#sule; *0-mg/mL sus#ension 1mtricitabine (1mtriva) 200-mg ca#sule; *0-mg/mL oral solution Lamivu ine (1#ivir)
Adverse Events
!"#ersensitivit" reaction (ma" inclu e $ever% ras&% nausea% vomiting% iarr&ea% malaise% s&ortness o$ breat&% coug&% #&ar"ngitis) -60 .g/ ,00 mg Peri#&eral neuro#at&"% #ancreatitis% PO q nausea% lactic aci osis 060 .g/ 2+0 mg PO q 2inimal to)icit"% &"#er#igmentation
200 mg PO q or 2,0 mg (2, mL) oral solution PO q *+0-mg% 300-mg 300 mg PO q tablet; or *0-mg/mL oral *+0 mg PO bi solution *+-mg% 20-mg% -60 .g/ ,0 mg 30-mg% ,0-mg PO bi ca#sule; *-mg/mL oral 060 .g/ 30 mg solution PO bi 300-mg tablet 300 mg PO q
2inimal to)icit"
Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% li#oatro#&"% &"#erli#i emia 5ausea% vomiting% iarr&ea% &ea ac&e% ast&enia% renal insu$$icienc" Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% stomatitis 5ausea% vomiting% &ea ac&e% ast&enia% anemia% neutro#enia
0637+-mg% 067+- 067+ mg PO ti mg tablet Zi ovu ine (8etrovir) 300-mg tablet% 300 mg PO bi *00-mg ca#sule; or *0-mg/mL oral 200 mg PO ti solution; *0-mg/mL intravenous solution Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 'elavir ine (8escri#tor) *00-mg% 200-mg ,00 mg PO ti 8as&% &ea ac&e tablets 1$aviren9 (3ustiva) 600-mg tablet; 600 mg PO q 8as&% :53 (eg% somnolence% vivi 200-mg ca#sule reams% con$usion% visual &allucinations) 1travirine (;ntelence) *00 mg tablet 200 mg PO bi 8as&% nausea 5evira#ine ((iramune) 200-mg tablet; 200 mg PO 8as&% &e#atitis *0-mg/mL bi a
sus#ension Protease inhibitors (PIs) Ata9anavir (8e"ata9) *+0-mg% 200mg% 300-mg ca#sules
,00 mg PO q or 300 mg < ritonavir *00 mg PO q 'arunavir (Pre9ista) ,00-mg% 600-mg =00 mg q < tablets ritonavir *00 mg PO q b or 600 mg bi < ritonavir *00 mg PO bi >osam#renavir (Le)iva) 700-mg tablet; 700 mg bi < +0-mg/mL oral ritonavir *00 sus#ension mg PO bi or *,00 mg PO bi or *,00 mg < ritonavir *00200 mg PO q b ;n inavir (:ri)ivan) *00-mg% 200=00 mg PO q=& mg% 333-mg% =00 mg PO bi ,00-mg ca#sules < ritonavir *00200 mg PO bi Lo#inavir/ritonavir 200-mg/+0-mg ,00 mg/*00 mg (?aletra) tablet; PO bi or =0-mg/20-mg =00 mg/200 mg #er mL oral PO q b solution 5el$inavir ((irace#t) 2+0-mg% 62+-mg *2+0 mg PO tablets bi or 7+0 mg PO ti (5el$inavir cannot be booste 6) 8itonavir (5orvir) *00-mg so$t @oosting ose gelatin ca#sule $or ot&er =0-mg/mL oral #rotease solution in&ibitors/ *00,00 mg/ (re$er to ot&er #rotease in&ibitors $or s#eci$ic ose) 5onboosting ose (8itonavir use as sole #rotease in&ibitor)/ 600
;n irect &"#erbilirubinemia% #rolonge P8 interval% &"#ergl"cemia 8as&% nausea% iarr&ea% &"#erli#i emia% &"#ergl"cemia
5e#&rolit&iasis% nausea% in irect &"#erbilirubinemia% &"#erli#i emia% &"#ergl"cemia 5ausea% vomiting% iarr&ea% ast&enia% &"#erli#i emia% &"#ergl"cemia 'iarr&ea% &"#erli#i emia% &"#ergl"cemia
3aquinavir (;nvirase)
4i#ranavir (A#tivus)
mg bi c *000 mg < ritonavir *00 mg PO bi Anbooste saquinavir is not recommen e +00 mg < ritonavir 200 mg PO bi Anbooste ti#ranavir is not recommen e ,00 mg PO bi
!e#atoto)icit"% ras&% &"#erli#i emia% &"#ergl"cemia% intracranial &emorr&age (rare cases re#orte )
Chemo ine receptor antagonist (CCR! antagonist) 2araviroc (3el9entr") *+0-mg% 300-mg 300 mg PO bi :onsti#ation% i99iness% in$ection% tablets *+0 mg PO bi ras& (:BP3A, in&ibitors C in ucers) 600 mg PO bi (:BP3A, in ucers) Fusion inhibitor (FI) 1n$uvirti e (>u9eon) D0-mg/mL D0 mg 3: bi ;nFection-site reactions (eg% #ain% #oE er $or er"t&ema% in uration% no ules) inFection Combination "ormulations 1#9icom - Abacavir (600 mg) < lamivu ine (300 mg) q 4ri9ivir - Abacavir (300 mg) < lamivu ine (*+0 mg) < 9i ovu ine (300 mg) bi 4ruva a - 4eno$ovir (300 mg) < emtricitabine (200 mg) q Atri#la - 4eno$ovir (300 mg) < emtricitabine (200 mg) < e$aviren9 (600 mg) q :ombivir - Zi ovu ine (300 mg) < lamivu ine (*+0 mg) bi Name Dosage Adult Dose Adverse Events Form(s) Nucleoside reverse transcriptase inhibitors (NRTIs) Abacavir (Ziagen) 300-mg tablet; 600 mg PO q !"#ersensitivit" reaction (ma" 20-mg/mL oral or inclu e $ever% ras&% nausea% solution 300 mg PO bi vomiting% iarr&ea% malaise% s&ortness o$ breat&% coug&% #&ar"ngitis) 'i anosine ((i e)) *2+-mg% 200-60 .g/ ,00 mg Peri#&eral neuro#at&"% #ancreatitis% mg% 2+0-mg% PO q nausea% lactic aci osis ,00-mg entericcoate ca#sule; 060 .g/ 2+0 mg 3
*0-mg/mL sus#ension 1mtricitabine (1mtriva) 200-mg ca#sule; *0-mg/mL oral solution Lamivu ine (1#ivir)
200 mg PO q or 2,0 mg (2, mL) oral solution PO q *+0-mg% 300-mg 300 mg PO q tablet; or *0-mg/mL oral *+0 mg PO bi solution *+-mg% 20-mg% -60 .g/ ,0 mg 30-mg% ,0-mg PO bi ca#sule; *-mg/mL oral 060 .g/ 30 mg solution PO bi 300-mg tablet 300 mg PO q
2inimal to)icit"
Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% li#oatro#&"% &"#erli#i emia 5ausea% vomiting% iarr&ea% &ea ac&e% ast&enia% renal insu$$icienc" Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% stomatitis 5ausea% vomiting% &ea ac&e% ast&enia% anemia% neutro#enia
0637+-mg% 067+- 067+ mg PO ti mg tablet Zi ovu ine (8etrovir) 300-mg tablet% 300 mg PO bi *00-mg ca#sule; or *0-mg/mL oral 200 mg PO ti solution; *0-mg/mL intravenous solution Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 'elavir ine (8escri#tor) *00-mg% 200-mg ,00 mg PO ti 8as&% &ea ac&e tablets 1$aviren9 (3ustiva) 600-mg tablet; 600 mg PO q 8as&% :53 (eg% somnolence% vivi 200-mg ca#sule reams% con$usion% visual &allucinations) 1travirine (;ntelence) *00 mg tablet 200 mg PO bi 8as&% nausea 5evira#ine ((iramune) 200-mg tablet; 200 mg PO 8as&% &e#atitis a *0-mg/mL bi sus#ension Protease inhibitors (PIs) Ata9anavir (8e"ata9) *+0-mg% 200,00 mg PO q ;n irect &"#erbilirubinemia% mg% 300-mg or #rolonge P8 interval% ca#sules 300 mg < &"#ergl"cemia ritonavir *00 mg PO q 'arunavir (Pre9ista) ,00-mg% 600-mg =00 mg q < 8as&% nausea% iarr&ea% tablets ritonavir *00 &"#erli#i emia% &"#ergl"cemia mg PO q b or 600 mg bi < ritonavir *00
mg PO bi >osam#renavir (Le)iva) 700-mg tablet; 700 mg bi < +0-mg/mL oral ritonavir *00 sus#ension mg PO bi or *,00 mg PO bi or *,00 mg < ritonavir *00200 mg PO q b ;n inavir (:ri)ivan) *00-mg% 200=00 mg PO q=& mg% 333-mg% =00 mg PO bi ,00-mg ca#sules < ritonavir *00200 mg PO bi Lo#inavir/ritonavir 200-mg/+0-mg ,00 mg/*00 mg (?aletra) tablet; PO bi or =0-mg/20-mg =00 mg/200 mg #er mL oral PO q b solution 5el$inavir ((irace#t) 2+0-mg% 62+-mg *2+0 mg PO tablets bi or 7+0 mg PO ti (5el$inavir cannot be booste 6) 8itonavir (5orvir) *00-mg so$t @oosting ose gelatin ca#sule $or ot&er =0-mg/mL oral #rotease solution in&ibitors/ *00,00 mg/ (re$er to ot&er #rotease in&ibitors $or s#eci$ic ose) 5onboosting ose (8itonavir use as sole #rotease in&ibitor)/ 600 mg bi c 3aquinavir (;nvirase) +00-mg tablet; *000 mg < 200-mg &ar ritonavir *00 gelatin ca#sule mg PO bi Anbooste saquinavir is not recommen e 4i#ranavir (A#tivus) 2+0-mg so$t +00 mg < gelatin ca#sule ritonavir 200 mg PO bi Anbooste
5e#&rolit&iasis% nausea% in irect &"#erbilirubinemia% &"#erli#i emia% &"#ergl"cemia 5ausea% vomiting% iarr&ea% ast&enia% &"#erli#i emia% &"#ergl"cemia 'iarr&ea% &"#erli#i emia% &"#ergl"cemia
!e#atoto)icit"% ras&% &"#erli#i emia% &"#ergl"cemia% intracranial &emorr&age (rare cases re#orte )
ti#ranavir is not recommen e Integrase inhibitor (II) 8altegravir (;sentress) ,00-mg tablet ,00 mg PO bi 5ausea% iarr&ea% &ea ac&e% :? elevations% m"o#at&"/r&ab om"ol"sis (rare)
Chemo ine receptor antagonist (CCR! antagonist) 2araviroc (3el9entr") *+0-mg% 300-mg 300 mg PO bi :onsti#ation% i99iness% in$ection% tablets *+0 mg PO bi ras& (:BP3A, in&ibitors C in ucers) 600 mg PO bi (:BP3A, in ucers) Fusion inhibitor (FI) 1n$uvirti e (>u9eon) D0-mg/mL D0 mg 3: bi ;nFection-site reactions (eg% #ain% #oE er $or er"t&ema% in uration% no ules) inFection Combination "ormulations 1#9icom - Abacavir (600 mg) < lamivu ine (300 mg) q 4ri9ivir - Abacavir (300 mg) < lamivu ine (*+0 mg) < 9i ovu ine (300 mg) bi 4ruva a - 4eno$ovir (300 mg) < emtricitabine (200 mg) q Atri#la - 4eno$ovir (300 mg) < emtricitabine (200 mg) < e$aviren9 (600 mg) q :ombivir - Zi ovu ine (300 mg) < lamivu ine (*+0 mg) bi
G'osing gui es assume an absence o$ rug- rug interactions (e)ce#t ritonavir) an normal renal an &e#atic $unction6 a A minister 200 mg q $or 2 Eee.s% t&en increase to 200 mg bi 6 b A##rove onl" $or antiretroviral treatmentHnaIve #atients c 4itrate ose over *, a"s% beginning Eit& 300 mg bi on a"s *-2% ,00 mg bi on a"s 3-+% an +00 mg bi on a"s 6-*36 A##rove onl" $or antiretroviral treatmentHe)#erience #atients Eit& rug resistance